Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

Key Takeaways Biogen is set to report Q3 2025 results on Oct. 30, with expectations for another earnings beat.Lower MS drug sales are likely to be offset by gains from Skyclarys, Zurzuvae, and Alzheimer's drug Leqembi.Sales of the spinal muscular atrophy drug, Spinraza, are likely to have declined due to lower demand. We expect Biogen (BIIB) to beat expectations when it reports third-quarter 2025 results on Oct. 30, before market open. In the last reported quarter, the company's earnings beat expectations b ...